**ZELEZNIK-LE**

Schmidt CR, Achille NJ, Kuntimaddi A, Boulton AM, Leach BI, Zhang S, Zeleznik-Le NJ, Bushweller JH. **BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity**. Blood Cancer Discov. 2020 Sep;1(2):162-177. doi: 10.1158/2643-3230.BCD-20-0036. PMID: 32954361; PMCID: PMC7497807.

Perez C, Prajapati K, Burke B, Plaza-Rojas L, **Zeleznik-Le NJ**, Guevara-Patino JA. **NKG2D signaling certifies effector CD8 T cells for memory formation**. J Immunother Cancer. 2019 Feb 18;7(1):48. doi: 10.1186/s40425-019-0531-2. PMID: 30777125; PMCID: PMC6380053.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, …, **Zeleznik-Le NJ**, …, Chen J. **miR-196b directly** **targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged** **leukaemia**. Nat Commun. 2018 Apr 10;9:16192. doi: 10.1038/ncomms16192. Erratum for: Nat Commun. 2012 Feb 21;3:688. PMID: 29633759; PMCID: PMC5898456.

**Zeleznik-Le NJ**. **One Step Forward in the Challenging Arena of MLL-AF4 Leukemia**. Cancer Cell. 2016 Nov 14;30(5):657-658. doi:10.1016/j.ccell.2016.10.017. PMID: 27846384.

Asimes A, Torcaso A, Pinceti E, Kim CK, **Zeleznik-Le NJ**, Pak TR. **Adolescent binge-pattern alcohol exposure alters genome-wide DNA methylation patterns in the hypothalamus of alcohol-naïve male offspring**. Alcohol. 2017 May;60:179-189.doi: 10.1016/j.alcohol.2016.10.010. Epub 2016 Oct 24. PMID: 27817987; PMCID:PMC5403620.

Mian YA, **Zeleznik-Le NJ**. **The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1**. Leuk Res. 2016 Jul;46:51-60.doi: 10.1016/j.leukres.2016.04.006. Epub 2016 Apr 16. PMID: 27123834; PMCID:PMC4899285.

Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, …, **Zeleznik-Le NJ**. **Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia** **patients**. Leuk Res. 2016 Mar;42:68-74. doi: 10.1016/j.leukres.2016.01.004. Epub 2016 Jan 15. PMID: 26818573; PMCID: PMC4779662.

Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M, **Zeleznik-Le NJ**, Bushweller JH. **Degree of recruitment of DOT1L to MLL-AF9 defines** **level of H3K79 Di- and tri-methylation on target genes and transformation potential**. Cell Rep. 2015 May 5;11(5):808-20. doi: 10.1016/j.celrep.2015.04.004. Epub 2015 Apr 23. PMID: 25921540; PMCID: PMC4426023.

**Zeleznik-Le NJ**. **Introduction to progress and promise of epigenetics for diagnosis and therapy in cancer**. Cancer Genet. 2015 May;208(5):165-6. doi:10.1016/j.cancergen.2015.04.003. Epub 2015 Apr 14. PMID: 25981828.

You D, Xin J, Volk A, Wei W, Schmidt R, Scurti G, Nand S, Breuer EK, …, **Zeleznik-Le NJ**, Zhang J. **FAK mediates a** **compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells**. Cell Rep. 2015 Mar 31;10(12):2055-68. doi: 10.1016/j.celrep.2015.02.056. Epub 2015 Mar 19. PMID: 25801032; PMCID: PMC7001526.

Brockway S, **Zeleznik-Le NJ**. **WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia**. Cancer Genet. 2015 May;208(5):279-87. doi:10.1016/j.cancergen.2015.01.001. Epub 2015 Jan 20. PMID: 25732734; PMCID:PMC4466047.

Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, **Zeleznik-Le NJ**, Zhang J, Qiu W. **FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis**. Hepatology. 2015 Jan;61(1):214-26. doi: 10.1002/hep.27402. Epub 2014 Nov 25. PMID: 25163657; PMCID: PMC4280291.

Lokken AA, Achille NJ, Chang MJ, Lin JJ, Kuntimaddi A, Leach BI, Malik B, Nesbit JB, …, **Zeleznik-Le NJ**, Hemenway CS. **Importance of a** **specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or** **AFF1/4**. Leuk Res. 2014 Nov;38(11):1309-15. doi: 10.1016/j.leukres.2014.08.010. Epub 2014 Aug 24. PMID: 25282333; PMCID: PMC4253547.

**Zeleznik-Le NJ**, Testa JR. **In memoriam: Janet D. Rowley, MD (April 5, 1925-December 17, 2013)**. Cancer Genet. 2014 Jan-Feb;207(1-2):46-7. doi:10.1016/j.cancergen.2014.01.005. PMID: 24795993.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, **Zeleznik-Le NJ**, Chen J, …, Grimes HL. **Therapeutic antagonists of microRNAs deplete** **leukemia-initiating cell activity**. J Clin Invest. 2014 Jan;124(1):222-36. doi: 10.1172/JCI66005. Epub 2013 Dec 16. PMID: 24334453; PMCID: PMC3871218.

Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, Bushweller JH, **Zeleznik-Le NJ**. **Functional specificity of CpG DNA-binding CXXC** **domains in mixed lineage leukemia**. J Biol Chem. 2013 Oct 11;288(41):29901-10. doi: 10.1074/jbc.M113.474858. Epub 2013 Aug 29. PMID: 23990460; PMCID: PMC3795288.

Zhang J, Seet CS, Sun C, Li J, You D, Volk A, Breslin P, Li X, …, **Zeleznik-Le NJ**, …, Zhang J. **p27kip1 maintains a subset of leukemia stem** **cells in the quiescent state in murine MLL-leukemia**. Mol Oncol. 2013 Dec;7(6):1069-82. doi: 10.1016/j.molonc.2013.07.011. Epub 2013 Aug 20. PMID:

23988911; PMCID: PMC3898829.

Lokken AA, **Zeleznik-Le NJ**. **Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML**. Cancer Cell. 2012 Apr17;21(4):451-3. doi: 10.1016/j.ccr.2012.03.027. PMID: 22516254; PMCID:PMC3996681.

Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, …, **Zeleznik-Le NJ**, …, Chen J. **miR-196b directly targets both** **HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia**. Nat Commun. 2012 Feb 21;3:688. doi: 10.1038/ncomms1681. Erratum in: Nat Commun. 2018 Apr 10;9:16192. PMID: 22353710; PMCID: PMC3514459.

Zook EC, Krishack PA, Zhang S, **Zeleznik-Le NJ**, Firulli AB, Witte PL, Le PT. **Overexpression of Foxn1 attenuates age-associated thymic involution and prevents** **the expansion of peripheral CD4 memory T cells**. Blood. 2011 Nov 24;118(22):5723-31. doi: 10.1182/blood-2011-03-342097. Epub 2011 Sep 9. PMID: 21908422; PMCID: PMC3228493.

Chang MJ, Wu H, Achille NJ, Reisenauer MR, Chou CW, **Zeleznik-Le NJ**, Hemenway CS, Zhang W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010 Dec 15;70(24):10234-42. doi: 10.1158/0008-5472.CAN-10-3294. PMID: 21159644; PMCID: PMC3040779.

Mian YA, **Zeleznik-Le NJ**. **MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets**. Curr Drug Targets. 2010 Jul;11(7):801-11. doi: 10.2174/138945010791320872. PMID: 20370647; PMCID: PMC2987689.

Birch NW, **Zeleznik-Le NJ**. **Glycogen synthase kinase-3 and leukemia: restoring the balance**. Cancer Cell. 2010 Jun 15;17(6):529-31. doi:10.1016/j.ccr.2010.05.017. PMID: 20541696; PMCID: PMC2987688.

Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, …, **Zeleznik-Le NJ**, …, Chen J. **Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia**. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3710-5. doi: 10.1073/pnas.0914900107. Epub 2010 Feb 2. PMID: 20133587; PMCID: PMC2840429.

Cierpicki T, Risner LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, Shultis DD, **Zeleznik-Le NJ**, Bushweller JH. **Structure of the MLL CXXC domain-DNA** **complex and its functional role in MLL-AF9 leukemia**. Nat Struct Mol Biol. 2010 Jan;17(1):62-8. doi: 10.1038/nsmb.1714. Epub 2009 Dec 13. PMID: 20010842; PMCID: PMC2908503.

Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, … Rowley JD, **Zeleznik-Le NJ**. **Regulation of** **mir-196b by MLL and its overexpression by MLL fusions contributes to** **immortalization**. Blood. 2009 Apr 2;113(14):3314-22. doi: 10.1182/blood-2008-04-154310. Epub 2009 Feb 2. PMID: 19188669; PMCID: PMC2665896.

Chen J, Santillan DA, Koonce M, Wei W, Luo R, Thirman MJ, **Zeleznik-Le NJ**, Diaz MO. **Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic** **stem cell immortalization**. Cancer Res. 2008 Aug 1;68(15):6199-207. doi: 10.1158/0008-5472.CAN-07-6514. PMID: 18676843; PMCID: PMC2734520.

Erfurth FE, Popovic R, Grembecka J, Cierpicki T, Theisler C, Xia ZB, Stuart T, Diaz MO, Bushweller JH, **Zeleznik-Le NJ**. **MLL protects CpG clusters from** **methylation within the Hoxa9 gene, maintaining transcript expression**. Proc Natl Acad Sci U S A. 2008 May 27;105(21):7517-22. doi: 10.1073/pnas.0800090105. Epub 2008 May 15. PMID: 18483194; PMCID: PMC2396713.

Popovic R, Erfurth F, **Zeleznik-Le N**. **Transcriptional complexity of the HOXA9 locus**. Blood Cells Mol Dis. 2008 Mar-Apr;40(2):156-9. doi:10.1016/j.bcmd.2007.07.016. Epub 2007 Oct 3. PMID: 17916434; PMCID: PMC2268101.

Baron BW, **Zeleznik-Le N**, Baron MJ, Theisler C, Huo D, Krasowski MD, Thirman MJ, Baron RM, Baron JM. **Repression of the PDCD2 gene by BCL6 and the** **implications for the pathogenesis of human B and T cell lymphomas**. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7449-54. doi: 10.1073/pnas.0701770104. Epub 2007 Apr 27. PMID: 17468402; PMCID: PMC1863460.

Santillan DA, Theisler CM, Ryan AS, Popovic R, Stuart T, Zhou MM, Alkan S, **Zeleznik-Le NJ**. **Bromodomain and histone acetyltransferase domain specificities** **control mixed lineage leukemia phenotype**. Cancer Res. 2006 Oct 15;66(20):10032-9. doi: 10.1158/0008-5472.CAN-06-2597. PMID: 17047066.

Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, **Zeleznik-Le NJ**. **The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression**. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14028-33. doi: 10.1073/pnas.0506464102. Epub 2005 Sep 16. PMID: 16169901; PMCID: PMC1236570.

Popovic R, **Zeleznik-Le NJ**. **MLL: how complex does it get?** J Cell Biochem. 2005 May 15;95(2):234-42. doi: 10.1002/jcb.20430. PMID: 15779005.

Vazquez I, Lahortiga I, Agirre X, Larrayoz MJ, Vizmanos JL, Ardanaz MT, **Zeleznik-Le NJ**, Calasanz MJ, Odero MD. **Cryptic ins(2;11) with clonal evolution** **showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient** **with AML-M2**. Leukemia. 2004 Dec;18(12):2041-4. doi: 10.1038/sj.leu.2403535. PMID: 15483676.

Zhang Y, **Zeleznik-Le N**, Emmanuel N, Jayathilaka N, Chen J, Strissel P, Strick R, Li L, Neilly MB, …, Rowley JD. **Characterization of genomic breakpoints in MLL and CBP in leukemia patients** **with t(11;16)**. Genes Chromosomes Cancer. 2004 Nov;41(3):257-65. doi: 10.1002/gcc.20077. PMID: 15334549.

Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, Sanchez R, **Zeleznik-Le NJ**, Ronai Z, Zhou MM. **Structural mechanism of the bromodomain of the** **coactivator CBP in p53 transcriptional activation**. Mol Cell. 2004 Jan 30;13(2):251-63. doi: 10.1016/s1097-2765(03)00528-8. PMID: 14759370.

Xia ZB, Anderson M, Diaz MO, **Zeleznik-Le NJ**. **MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein**. Proc Natl Acad Sci U S A. 2003 Jul8;100(14):8342-7. doi: 10.1073/pnas.1436338100. Epub 2003 Jun 26. PMID:12829790; PMCID: PMC166231.

Echlin-Bell DR, Smith LL, Li L, Strissel PL, Strick R, Gupta V, Banerjee J, Larson R, …, **Zeleznik-Le N**, Rowley JD. **Polymorphisms in the MLL breakpoint cluster region (BCR)**. Hum Genet. 2003 Jul;113(1):80-91. doi: 10.1007/s00439-003-0936-2. Epub 2003 Mar 29. PMID: 12665971.

Kuefer MU, Chinwalla V, **Zeleznik-Le NJ**, Behm FG, Naeve CW, Rakestraw KM, Mukatira ST, Raimondi SC, Morris SW. **Characterization of the MLL partner gene** **AF15q14 involved in t(11;15)(q23;q14)**. Oncogene. 2003 Mar 6;22(9):1418-24. doi: 10.1038/sj.onc.1206272. PMID: 12618768.

Chinwalla V, Chien A, Odero M, Neilly MB, **Zeleznik-Le NJ**, Rowley JD. **A** **t(11;15) fuses MLL to two different genes, AF15q14 and a novel gene MPFYVE on** **chromosome 15**. Oncogene. 2003 Mar 6;22(9):1400-10. doi: 10.1038/sj.onc.1206273. PMID: 12618766.

Macara IG, Baldarelli R, Field CM, Glotzer M, Hayashi Y, Hsu SC, Kennedy MB, Kinoshita M, …, **Zeleznik-Le NJ**, Zieger B. **Mammalian septins nomenclature**. Mol Biol Cell. 2002 Dec;13(12):4111-3. doi:10.1091/mbc.e02-07-0438. PMID: 12475938; PMCID: PMC138619.

Odero MD, Vizmanos JL, Román JP, Lahortiga I, Panizo C, Calasanz MJ, **Zeleznik-Le NJ**, Rowley JD, Novo FJ. **A novel gene, MDS2, is fused to ETV6/TEL in** **a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome**. Genes Chromosomes Cancer. 2002 Sep;35(1):11-9. doi: 10.1002/gcc.10090. PMID: 12203785.

Baron BW, Anastasi J, Thirman MJ, Furukawa Y, Fears S, Kim DC, Simone F, Birkenbach M, …, **Zeleznik-Le N**, McKeithan TW. **The human** **programmed cell death-2 (PDCD2) gene is a target of BCL6 repression:** **implications for a role of BCL6 in the down-regulation of apoptosis**. Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2860-5. doi: 10.1073/pnas.042702599. Epub 2002 Feb 19. PMID: 11854457; PMCID: PMC122438.

Liedman D, **Zeleznik-Le N**. **Retroviral transduction model of mixed lineage leukemia fused to CREB binding protein**. Curr Opin Hematol. 2001 Jul;8(4):218-23.doi: 10.1097/00062752-200107000-00007. PMID: 11561159.

Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, **Zeleznik-Le NJ**, Mrózek K, Theil KS, Kees UR, …, Caligiuri MA. **The partial nontandem** **duplication of the MLL (ALL1) gene is a novel rearrangement that generates three** **distinct fusion transcripts in B-cell acute lymphoblastic leukemia**. Cancer Res. 2001 Jan 1;61(1):59-63. PMID: 11196198.

Odero MD, **Zeleznik-Le NJ**, Chinwalla V, Rowley JD. **Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation**. Genes Chromosomes Cancer. 2000 Dec;29(4):333-8. PMID: 11066077.

Lavau C, Du C, Thirman M, **Zeleznik-Le N**. **Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia**. EMBO J. 2000 Sep 1;19(17):4655-64. doi: 10.1093/emboj/19.17.4655.PMID: 10970858; PMCID: PMC302066.

Strissel PL, Strick R, Tomek RJ, Roe BA, Rowley JD, **Zeleznik-Le NJ**. **DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis**. Hum Mol Genet.2000 Jul 1;9(11):1671-9. doi: 10.1093/hmg/9.11.1671. PMID: 10861294.